Rapamycin, an inhibitor of the mammalian target of rapamycin complex 1 (mTORC1), up-regulating GP73, appears to be a medicine that, by decreasing the expression level of GP73, causes inhibition of cancer development [59]. This evidence concerns the gene GOLM1 and cancer.